.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SENSCIS trial evaluated nintedanib in adults with systemic sclerosis-associated interstitial lung disease, a population in whom progressive fibrosis can cause substantial morbidity. In this randomized placebo-controlled study, nintedanib reduced the annual rate of decline in forced vital capacity compared with placebo, supporting an antifibrotic treatment strategy in this form of connective-tissue-disease ILD. Diarrhea was the most frequent adverse event, making tolerability and patient counselling important parts of treatment planning. The study does not mean that every patient with systemic sclerosis should automatically receive nintedanib; rather, it adds evidence for a disease-modifying option when clinically meaningful ILD is present and progression is a concern. This aligns closely with the NAPCON ILD session's focus on connective-tissue-disease-associated ILD and antifibrotics beyond classic IPF. The clinically useful lesson is to identify ILD early, quantify disease burden and follow trajectory with symptoms, lung function and imaging. Treatment decisions then become part of an ongoing reassessment process rather than a one-time choice. SENSCIS is also a useful reference when discussing how the antifibrotic evidence base has expanded from IPF into broader fibrosing lung disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SENSCIS trial evaluated nintedanib in adults with systemic sclerosis-associated interstitial lung disease, a population in whom progressive fibrosis can cause substantial morbidity. In this randomized placebo-controlled study, nintedanib reduced the annual rate of decline in forced vital capacity compared with placebo, supporting an antifibrotic treatment strategy in this form of connective-tissue-disease ILD. Diarrhea was the most frequent adverse event, making tolerability and patient counselling important parts of treatment planning. The study does not mean that every patient with systemic sclerosis should automatically receive nintedanib; rather, it adds evidence for a disease-modifying option when clinically meaningful ILD is present and progression is a concern. This aligns closely with the NAPCON ILD session's focus on connective-tissue-disease-associated ILD and antifibrotics beyond classic IPF. The clinically useful lesson is to identify ILD early, quantify disease burden and follow trajectory with symptoms, lung function and imaging. Treatment decisions then become part of an ongoing reassessment process rather than a one-time choice. SENSCIS is also a useful reference when discussing how the antifibrotic evidence base has expanded from IPF into broader fibrosing lung disease.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
